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Abstract
Background: In recent years, the number of people with metabolic syndrome has continued to rise because of
changing eating habits, and accompanying hepatic steatosis patients have also increased. This study examined the
effect of guava leaf extract on liver fat accumulation using SHRSP.Z-Leprfa/IzmDmcr rats (SHRSP/ZF), which are a
metabolic syndrome model animal.
Method: Seven-week-old male SHRSP/ZF rats were divided into two groups, a control group and a guava leaf
extract (GLE) group. We gave 2 g/kg/day GLE or water by forced administration for 6 weeks. After the experimental
period, the rats were sacrificed and organ weight, hepatic lipids, serum aminotransferase and liver pathology were
examined. To search for a possible mechanism, we examined the changes of key enzyme and transcriptional
factors involved in hepatic fatty acid beta-oxidation.
Results: The triglyceride content of the liver significantly decreased in the GLE group in comparison with the
control group, and decreased fat-drop formation in the liver tissue graft in the GLE group was observed. In
addition, the improvement of liver organization impairments with fat accumulation restriction was suggested
because blood AST and ALT in the GLE group significantly decreased. Furthermore, it was supposed that the
activity of AMPK and PPARa significantly increased in the GLE group via the increase of adiponectin receptors.
These were thought to be associated with the decrease of the triglyceride content in the liver because AMPK and
PPARa in liver tissue control energy metabolism or lipid composition. On the other hand, insulin resistance was
suggested to have improved by the fatty liver improvement in GLE.
Conclusion: Our results indicate that administration of GLE may have preventive effects of hepatic accumulation
and ameliorated hepatic insulin resistance by enhancing the adiponectin beta-oxidation system. Guava leaf may be
potentially useful for hepatic steatosis without the side effects of long-term treatments.
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Background
In recent years, metabolic syndrome has attracted atten-
tion worldwide as it concerns type II diabetes, hyperlipi-
demia and hypertension developing against the
background of visceral obesity, and the pathogenic eluci-
dation of metabolic syndrome has been pushed forward.
Accumulation of excessive amounts of storage lipids
into adipose tissue causes adipocyte hypertrophy with
the development of obesity, subsequently resulting in
secretion abnormalities of FFA and adipocytokines such
as TNF-alpha, IL-6 and adiponectin derived from adipo-
cytes, which are involved in insulin resistance [1]. This
is the source of metabolic syndrome.
Hepatic steatosis, which develops when a large
amount of lipid is deposited in hepatocyte is the liver
manifestation of metabolic syndrome [2]. It is a com-
mon liver disease and is rapidly becoming a worldwide
public health problem [3]. Currently, there are no data
on the long-term administration of drugs for hepatic
steatosis and effective therapy for hepatic steatosis has
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not been established, so the treatment generally requires
an improved lifestyle, such as reducing a high calorie
intake and increasing exercise; however, many patients
have poor compliance. Therefore, the discovery of nutri-
ents that ameliorate fatty liver is of interest and value.
The guava tree (psidium guajava linn.) belongs to a
member of the Myrtaceae family, which range through-
out tropical and subtropical countries. It is commonly
used not only as food but also as folk medicine as an
antioxidant, anti-spasmodic, anti-allergy, anti-inflamma-
tory and anti-diabetic using extracts from the fruit, leaf,
bark or roots [4,5]. Leaves of this plant have been used
as folk medicine and are reported to contain several
compounds, such as various terpenoids [6,7], flavonoids
[8] and tannins [9]. Previous reports demonstrated the
effects of guava leaf extracts (GLE) against, for example,
diabetes [10-12]; however, there have not yet been pre-
cise studies of the effects of GLE on hepatosteatosis.
SHRSP.Z-Leprfa/IzmDmcr rats (SHRSP/ZF) were
established as a new model of metabolic syndrome by
crossing SHRSP rats (this model presents with marked
elevation of blood pressure) with Zucker Fatty rats.
SHRSP/ZF rats undergo a mutation in the leptin recep-
tor, and develop obesity, hyperlipidemia and insulin
resistance [13]; thus, they are good tool for the study of
metabolic syndrome-associated diabetes, hepatic steato-
sis and so on [14].
Recently, the search for appropriate hepatic steatosis
agents has focused on plants used in traditional medi-
cine. The present study investigated whether GLE exhi-
bits preventive effects against hepatic accumulation and
ameliorative hepatic insulin resistance, and the mechan-
isms behind such effects using SHRSP/ZF rats.
Methods
Animals
Six-week-old male SPF (specific pathogen free) SHRSP.
Z-Leprfa/IzmDmcr (SHRSP/ZF) rats were obtained from
Japan SLC (Shizuoka, Japan). All rats were housed in a
climate-controlled (temperature: 22-24°C, humidity: 40-
60%) light-regulated room with 12-hour light and dark
cycles. The rats were fed normal chow (CE-2) for 1
week to stabilize their metabolic condition. SHRSP/ZF
rats were allotted to 2 groups; a control group (not trea-
ted, n = 7) and a guava leaf 70% ethanol extract (GLE)
group (GLE gavage administered as 2 g/kg/day, supplied
by Beijing University of Chinese Medicine, which identi-
fied the biological materials, n = 7). We measured the
water and food intake and body weight (BW) of rats
daily.
At the conclusion of the 6-week treatment period,
after 12 h fasting, all rats were sacrificed. Their blood
samples were collected and sera were prepared by cen-
trifugation, frozen, and stored at -20°C until analysis.
The tissues were immediately harvested and cleaned for
measurement of tissue weight, and the liver was
promptly frozen in liquid nitrogen and stored at -80°C
for Western blotting and gene analysis. A portion of the
liver from individual rats was fixed overnight in 10% for-
malin for histological analysis.
All procedures were carried out in accordance with
the guiding principles for the care and use of animals in
the field of physiological sciences established by the
Physiological Society of Japan, and the guidelines for the
care and use of animals set by Mukogawa University.
Blood analysis
The concentrations of serum aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) were mea-
sured using the corresponding commercial enzyme kit
(Wako Pure Chemicals, Osaka).
Tissue lipid analysis
Liver tissue (10 mg) was homogenized in 0.1 M acetic
acid and hepatic lipid extracted with chloroform-metha-
nol, as described by Folch et al. [15]. Chloroform layers
were dried and dissolved in isopropanol containing 10%
Triton X-100. Triglyceride, cholesterol and FFA concen-
trations were then determined enzymatically using each
kit (Wako).
Histological analysis of the liver
After fixation in 10% formalin buffer, liver tissue was
embedded in paraffin. The liver sections were stained
with hematoxylin and eosin (HE).
Assay of hepatic CPT activity
A piece of liver was homogenized in 10 vol of 0.25 M
sucrose, 1 mM EDTA and 3 mM Tris-HCl (pH7.2) solu-
tion buffer. After precipitating the nuclei fraction, the
supernatant was used for enzyme activity. The activity
of carnitine palmitoyl transferase (CPT) was determined
as described previously [16]. The reaction solution con-
tained 58 mM Tris-HCl (pH8.0), 1.25 mM EDTA, 0.25
mM 5, 5’-dithiobis-2-nitrobenzoic acid, 0.1% Triton-X
and 0.04 mM palmitoyl-CoA. This solution was equili-
brated at 30°C. The reaction was initiated by the addi-
tion of 0.1 mL supernatant and absorbance was
monitored at 412 nm until it stabilized. After the addi-
tion of 1.25 mM L-carnitine, the rate was monitored
and the difference between with and without L-carnitine
gave the L-carnitine-dependent rate.
Primary antibodies used
Immunoblotting was performed with the following com-
mercially available antibodies; anti-rabbit AMPK, anti-
rabbit phospho- AMPK, anti-rabbit Akt, anti-rabbit
phospho-Akt (Ser473, Thr308), were from Cell Signaling
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Technology (Beverly, MA). Anti-mouse b-actin was
obtained from Sigma (St. Louis, MO).
Western blot analysis
The liver tissue was homogenized with ice-cold homo-
genized buffer containing 50 mM Tris-HCl (pH7.4), 100
mM NaCl, 1% Nonidet-P40, 0.25% Na deoxycholate,
0.1% SDS, 1 mM EDTA, 50 mM NaF, 2 mM Na3VO4,
30 mM Na pyrophosphate, 2 mM PMSF, 1 mM benza-
midine, 0.02 g/mL trypsin inhibitor, 0.02 g/mL leupep-
tin, and 0.02 g/mL aprotinin. After incubation for 2
hours, lysates were centrifuged at 15,000 rpm for 20
min and supernatants were isolated. Proteins were
extracted by boiling the tissues in 0.5 mmol/l Tris/HCl,
pH6.8, glycerol, 10% SDS, 0.1% bromophenol blue and
2-mercaptethanol. The proteins (25 μg/lean) were elec-
trophoresed using 7.5%-12.5% SDS-PAGE gel at 100 V
for 2 hours. After fractionating, the proteins were trans-
ferred onto a PVDF membrane (Amersham Life Science
Inc. Buckinghamshire) at 100 mA for 2 hours. The
membrane was blocked in Blocking One (Nacalai Tes-
que, Kyoto) for 20 min. After appropriate blocking, the
blot was incubated with the primary antibody in anti-
body solution 1 (Toyobo, Osaka) overnight. It was then
washed with TTBS and finally incubated for 1 h with a
1:5000 dilution of anti-rabbit and mouse IgG-horserad-
ish peroxidase. Detection was achieved using an ECL kit
(Amersham Inc. Buckinghamshire). b-actin was used as
an internal control. The density of the bands was mea-
sured using NIH Image.
Real-time RT PCR
Total RNA was extracted from the liver using Sepasol-
RNA I Super G (Nacalai Tesque, Kyoto). From each
sample, total RNA was reverse transcribed to cDNA
using the ReverTra Ace qPCR RT Kit (Toyobo). THUN-
DERBIRD SYBR qPCR Mix was used for quantitative
real-time RT-PCR analysis of each gene expression. The
primers are listed in Table 1. Amplification was per-
formed with a real-time PCR system (ABI Prism 7000).
The results are expressed as a relative value after nor-
malization to the b-actin expression.
Statistical analysis
Data are expressed as the mean ± SEM. Statistical analy-
sis of the data was performed by Student’s t-test. A p-
value less than 0.05 was considered significant.
Results
Effect of GLE treatment on metabolic parameters
The metabolic parameters are shown in Table 2. After
the 6-week treatment period, the body weight of the
GLE group rats had significantly decreased compared
with the control group (p = 0.027). BW gain was about
20% lower in the GLE group. Organ weight is also
shown. Administration of GLE indicated a significant
decrease in adipose weight (p = 0.007). In terms of liver
weight reduction, liver TG was significantly reduced by
GLE administration. On the other hand, GLE did not
affect cholesterol and FFA in the liver. Meanwhile, daily
food intake per cage did not differ among groups in
either long-term experiment (data not shown).
Histological examination and serum aminotransferase
The histological examination of livers from the experi-
mental rats is shown in Figure 1. It can be seen that
livers in the control group appeared to show a fatty
liver. Administration of GLE showed a positive effect,
and the GLE group improved and the liver appeared to
be less fatty than the control group in the filtration of
hepatocytes. This result was exemplified by the fact that
levels of serum alanine transaminase (ALT) and aspar-
tate transaminase (AST) in the GLE group were signifi-
cantly lower than in the control group (Table 3: p =
0.019 and p = 0.049).
Changes in gene expression of adiponectin receptors
To elucidate the molecular mechanism of the lipid-low-
ering effect of GLE, we characterized adiponectin recep-
tor gene expression in the liver. The results










Table 2 Effect of GLE on lipid parameters in SHRSP-fatty
rats
control GLE
Body Weight (n = 6) (n = 5)
initial (g) 208.50 ± 9.12 216.40 ± 8.95
final (g) 405.17 ± 5.54 376.20 ± 10.04 *
gain (g) 196.67 ± 7.40 159.80 ± 17.05
Organ Weight (n = 5) (n = 4)
liver (g) 13.55 ± 0.56 12.39 ± 0.37
adipose (g) 9.76 ± 0.35 8.41 ± 0.32 *
Liver lipid (n = 5) (n = 4)
TG (mg/dL) 21.44 ± 1.42 12.85 ± 1.28 *
cholesterol (mg/dL) 26.78 ± 1.08 24.54 ± 0.76
FFA (mEq/L) 0.31 ± 0.01 0.38 ± 0.06
Data are the mean ± SEM. * p < 0.05 different from the control group. Rats
were administered the treatment for 6 weeks
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demonstrated significantly increased AdipoR1 (Figure
2A; 0.311 ± 0.011 vs 0.725 ± 0.166: p = 0.047 n = 4)
and AdipoR2 (Figure 2B; 0.424 ± 0.034 ± vs 0.669 ±
0.094: p = 0.049 n = 4) in the GLE group compared
with the control group.
AMPK phosphorylation and PPARa expression
Adiponectin activity stimulates AMPK and PPARa,
which are involved in liver lipid metabolism. Activity of
AMPK was assessed by measuring phosphorylated
AMPK (p-AMPK). Compared with the control, GLE-
treated rats exhibited significantly increased p-AMPK
protein levels (Figure 2C; 0.559 ± 0.047 vs 0.672 ±
0.071: p = 0.014 n = 4). Likewise, PPARa mRNA
expression in the GLE group also became higher than in
the control group (Figure 2D; 9.208 ± 0.722 vs 12.618 ±
1.073: p = 0.039 n = 4).
Hepatic fatty acid beta-oxidation related enzyme
expression and activity
We researched the expression of genes and activity
involved in fatty acid beta-oxidation enzyme. First, we
measured the expression genes, medium-chain acyl-CoA
dehydrogenase (MCAD) and acyl-CoA oxidase (ACO),
which are rate-limiting fatty acid beta-oxidation
enzymes in mitochondria and peroxisome. In the GLE
group, both were elevated compared with the control
group (Figure 3A; 1.145 ± 0.094 vs 1.568 ± 0.117: p =
0.031 n = 4, and 3B; 1.296 ± 0.343vs 1.664 ± 0.036: p =
0.407 n = 4; differences were not statistically significant).
Similarly, mitochondrial fatty acid beta-oxidation in the
liver was increased after GLE administration, as
measured using hepatic CPT activity (Figure 4; 83.65 ±
7.346 vs 107.65 ± 3.488 U/L: p = 0.03 n = 4).
Effect of GLE treatment on Akt/PEPCK signaling in the
liver
The level of phosphorylation of Akt at ser473 in the
liver in the GLE group was significantly higher than in
the control group (Figure 5A; 1.56 ± 0.178 vs 2.41 ±
0.194: p = 0.015 n = 4), as determined by Western blot-
ting, because Akt is an important factor in insulin sig-
naling and the control of gluconeogenesis. Moreover,
the mRNA level of PEPCK, which is controlled by Akt
activity, was also decreased compared with the control
control GLE
Figure 1 Pathogenic description of the rat livers. Effect of oral
administration of GLE on the histological examination of livers from
SHRSP-fatty rats. Liver tissue sections were stained with HE and
examined under a light microscope. Data are representative images
(magnification × 100).
Table 3 Serum aminotransferase
control (n = 5) GLE (n = 4)
AST (IU/L) 47.23 ± 5.56 27.70 ± 1.31 *
ALT (IU/L) 24.37 ± 1.79 18.74 ± 1.41 *
Data are the mean ± SEM. * p < 0.05 different from the control group. Rats




























































































Figure 2 Hepatic factors involved in energy metabolism in rats.
Effect of GLE on hepatic energy metabolism factors in rat liver: (A)
AdipoR1 mRNA expression and (B) AdipoR2 mRNA expression (C)
rate of AMPK phosphorylation, level of Western blotting (D) PPAR-
alpha mRNA expression. Data are the mean ± SEM of n = 4 rats. * p








































Figure 3 Hepatic mRNA expression of enzymes involved in
beta-oxidation in rats. The expression of hepatic (A) MCAD and
(B) ACO in rats treated GLE. Data are the mean ± SEM of n = 4 rats.
* p < 0.05 different from the control group. Rats were administered
the treatment for 6 weeks.
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group (Figure 5B; 0.901 ± 0.125 vs 0.712 ± 0.085: p =
0.26 n = 4, differences were not statistically significant).
Discussion
The our major findings of the present study are as fol-
lows: 1) The administration of GLE had preventive
effects against hepatic lipid accumulation and amelio-
rated hepatic insulin resistance; 2) The mechanism for
this action was the increase of b-oxidation by increasing
adiponectin receptors.
SHRSP.Z-Leprfa/IzmDmcr rats (SHRSP/ZF rats) were
established as a model of metabolic syndrome. Specifi-
cally, they showed alterations in lipogenesis, such as
SCD-1, FAS and SREBP-1 in the liver. Abnormality of
these genes caused the accumulation of lipid droplets in
hepatocytes [17], and thus, they may be a good tool for
the study of fatty liver. Using these model rats, we
demonstrated that 6-week GLE treatment reduced body
weight, liver weight and fat weight. The most interesting
finding in our study was that GLE treatment amelio-
rated hepatic steatosis and decreased the accumulation
of triglyceride (TG) in the liver of SHRSP/ZF rats. This
was shown histologically and biochemically.
Alanine transaminase (ALT) is an important enzyme
found predominately in the liver. Significantly elevated
activity of ALT in serum often suggests its leakage from
damaged hepatocytes and reflects hepatic damage.
Aspartate aminotransferase (AST) is similar to ALT in
that it is another enzyme associated with the liver [18].
A slight rise of AST and the ALT can be appeared for
the fatty liver because of cellular membrane defect from
FFA, and they are used as diagnostic criteria of the fatty
liver. The decrease of serum ALT and AST by GLE also
accounts for the improvement of the liver histology and
less fat infiltration of hepatocytes.
In visceral obesity, adipocytokines such as TNFa,
resistin, IL-6 and FFA are secreted by enlarged fat cells
of the internal organs as adipose tissue and induce insu-
lin resistance [19-21]. As a result of insulin resistance,
glucose and fat metabolism decrease with the muscle,
and the release of fatty acid is promoted with adipose
tissue. Glucose and fatty acid are then supplied to the
liver excessively. Furthermore, the biosynthesis of fatty
acid is aggravated in the liver, and fat over-accumulates
in hepatocytes in conjunction with fatty acid supplied
from adipose tissue. On the other hand, b-oxidation,
which is the fatty acid metabolism system in hepato-
cytes, decreases. As a result, a fatty liver develops.
Adiponectin is one such adipocytokine secreted by
adipose tissue that has recently attracted much atten-
tion, because it has lipid metabolism promotion effects
and improves insulin resistance [22]. In the liver, adipo-
nectin stimulate glucose utilization and fatty acid com-
bustion via AMPK. Adiponectin also increases the
expression levels of PPARa and activates PPARa ligand,
thereby stimulating the expression enzyme involved in
fatty acid oxidation and decreasing tissue TG content
[23]. Expression of adiponectin is induced by the differ-
entiation of fat cells. In non-obese small fat cells, there
is a high expression of adiponectin; however, its tran-
scription is inhibited by obesity when a fat cell is
enlarged. In our first approach to find a possible
mechanism, we focused on adiponectin. We predicted
that secretion of adiponectin might increase in the GLE
group compared with the control group in rat adipose
tissue from the results of decreased body weight and fat
weight with GLE treatment; however, the serum adipo-
nectin level did not increase with GLE treatment (data
not shown). According to a past report, obesity
decreases not only plasma adiponectin but also adipo-
nectin receptor expression due to hyperinsulinemia [24].
We have already confirmed that SHRSP/ZF rat expres-
sion of adiponectin receptors is decreased compared
Figure 4 Effect of GLE on hepatic CPT activity in rats. Hepatic
CPT activity in rats administered the control or GLE for 6 weeks.


















































Figure 5 Effect of GLE on hepatic Akt/PEPCK signaling in rats.
Effect of GLE on hepatic insulin signaling factors: (A) rate of Akt
phosphorylation, level of (B) PEPCK mRNA expression in rat liver.
Data are the mean ± SEM of n = 4 rats. * p < 0.05 different from
the control group.
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with normal rats. In our study, GLE increased the
expression of adiponectin receptor 1 and 2, with the
activity of AMPK and mRNA expression of PPARa,
which is a downstream adiponectin receptor.
Fatty acid b-oxidation takes place in two cellular orga-
nelles, mitochondria and peroxisomes [25]. In liver cells,
it is proposed that mitochondrial oxidation might have
the largest impact on total b-oxidation [26]. Activation of
AMPK leads to a decrease in intracellular malonyl-CoA,
which is a precursor of the biogenesis of fatty acid and a
potent inhibitor of carnitine palmitoyltransferase (CPT)
[27,28]. CPT is a rate-limiting enzyme of mitochondrial
b-oxidation and plays an important role in the transport
of fatty acid to inside the mitochondria [26]. On the
other hand, PPARa controls the transcription of many
genes involved in lipid catabolism, such as medium-chain
acyl-CoA dehydrogenase (MCAD), acyl-CoA oxidase
(ACO) and also CPT. In our study, it was demonstrated
that CPT activity in the GLE group increased compared
with the control. In addition, we evaluated mRNA
expression; MCAD as a marker of enzyme mitochondrial
b-oxidation, and ACO as a marker of point to control
peroxisomal one [26]. In the GLE group, both were
higher than in the control group. Our results showed
that GLE treatment increases energy expenditure by
increasing fatty acid b-oxidation in liver cells. On the
other hand, SREBP-1 and FAS mRNA levels, which are
factors in lipogenesis and downstream AMPK, showed
no difference between them (data not shown).
Dysregulation of adiponectin and the decrease its
receptors play causal roles in the development of insulin
resistance [29]. A correlation has been reported that adi-
ponectin receptor gene expression was decreased in type
2 diabetic patients. Moreover, a previous study demon-
strated that AdipoR1/R2 knockout mice exhibited aggra-
vated insulin resistance through increased TG content,
inflammation and oxidative stress [30]. On the other
hand, adipocyte hypertrophy with the development of
obesity, subsequently resulting in secretion abnormal-
ities of FFA and adipocytokines such as TNF-a and IL-
6, which are involved in insulin resistance [1]. In this
study, Akt activity in the liver in the GLE group was sig-
nificantly higher than in the control group. Akt is an
important factor in insulin signaling and in the control
of gluconeogenesis. Moreover, the mRNA level of
PEPCK, which is controlled by Akt activity and rate-lim-
iting enzyme of gluconeogenesis, was also decreased
compared with the control group. In our other group
study, Guo et al. demonstrated that SHRSP/ZF rats trea-
ted with GLE had improvement glucose metabolism
without enhanced insulin secretion. These results might
suggest that GLE has an insulin resistance-improving
effect by improving fatty liver and reduced adipose tis-
sue due to a decreased adipocytokines.
Conclusion
In conclusion, GLE increased adiponectin receptors in the
liver and increased the activation of downstream AMPK
and the expression of PPARa. Furthermore, it promoted
fatty acid combustion by increasing the expression and
activation of b-oxidative enzymes. It reduced TG content
in the liver and, as a result, it improved insulin resistance
and the inhibition of glyconeogenesis by synergistic inter-
action with AMPK. Recently, it was reported that fasting
and exercise were factors increasing the expression of adi-
ponectin receptors [31-33]; however, this is not easy,
because they require a sustained effort and cause stress to
patients. In addition, troglitazone and rosiglitazone, which
are PPARg agonists, also increased the expression of adi-
ponectin receptors; however, they have risks when admi-
nistered preventively and long term to patients with a
previous condition such as metabolic syndrome because
hepatotoxicity is a side effect [34,35]. From our present
study, we suggest that guava leaf extract promotes fat
combustion, restricts fat accumulation in the liver by
increasing adiponectin receptor gene expression, and
improves insulin resistance. Because there are few side
effects of long-term treatment, guava leaf extract may be
potentially useful for hepatic steatosis.
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